HC Wainwright set a $14.00 price objective on Corium International (NASDAQ:CORI) in a research note issued to investors on Friday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

CORI has been the topic of several other research reports. Needham & Company LLC cut their price objective on shares of Corium International from $16.00 to $14.00 and set a buy rating on the stock in a report on Tuesday, December 26th. Cantor Fitzgerald restated a buy rating and set a $14.00 price objective on shares of Corium International in a report on Friday, December 22nd. Jefferies Group set a $10.00 price objective on shares of Corium International and gave the company a buy rating in a report on Sunday, October 29th. Zacks Investment Research upgraded shares of Corium International from a sell rating to a hold rating in a report on Tuesday, November 28th. Finally, BidaskClub downgraded shares of Corium International from a buy rating to a hold rating in a report on Saturday, February 3rd. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The stock presently has a consensus rating of Buy and an average price target of $12.86.

Corium International (NASDAQ CORI) traded up $0.17 on Friday, hitting $12.18. 207,713 shares of the stock traded hands, compared to its average volume of 196,123. Corium International has a 12-month low of $2.77 and a 12-month high of $13.93. The company has a current ratio of 2.70, a quick ratio of 2.60 and a debt-to-equity ratio of 2.41. The firm has a market capitalization of $441.51, a P/E ratio of -7.76 and a beta of 1.59.

Corium International (NASDAQ:CORI) last posted its quarterly earnings data on Thursday, November 16th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.43) by $0.07. Corium International had a negative net margin of 148.07% and a negative return on equity of 331.37%. research analysts expect that Corium International will post -1.47 EPS for the current fiscal year.

In related news, major shareholder Healthcare Master Fun Broadfin sold 500,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $10.96, for a total value of $5,480,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Life Sciences Maste Perceptive bought 510,000 shares of the company’s stock in a transaction that occurred on Thursday, January 18th. The stock was purchased at an average price of $12.54 per share, for a total transaction of $6,395,400.00. The disclosure for this purchase can be found here. 30.80% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently modified their holdings of the stock. New York State Common Retirement Fund purchased a new stake in Corium International in the second quarter valued at approximately $158,000. California State Teachers Retirement System purchased a new stake in Corium International in the second quarter valued at approximately $263,000. Teachers Advisors LLC purchased a new stake in Corium International in the second quarter valued at approximately $272,000. California Public Employees Retirement System purchased a new stake in Corium International in the fourth quarter valued at approximately $310,000. Finally, TIAA CREF Investment Management LLC purchased a new stake in Corium International in the second quarter valued at approximately $411,000. Hedge funds and other institutional investors own 89.15% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2018/02/10/hc-wainwright-reiterates-14-00-price-target-for-corium-international-cori.html.

About Corium International

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Analyst Recommendations for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.